以mTCRCAR T细胞靶向PRAME治疗急性髓系白血病
研究利用靶向PRAME肽-HLA复合物的TCR模拟抗体Pr20序列构建PRAME mTCRCAR T细胞,在表达PRAME的HLA-A2阳性AML细胞系和原代AML患者样本中显示靶点特异性和HLA介导的体外活性,在体内细胞来源异种移植模型中实现强效白血病清除并改善生存,干扰素γ处理靶细胞可增强其溶细胞活性。
要点
- PRAME在相当一部分儿童和成人AML中表达,在正常造血中不表达,是免疫治疗的理想靶点。
- PRAME mTCRCAR T细胞在OCI-AML2、THP-1细胞系及原代AML患者样本中显示靶点特异性和HLA介导的体外活性。
- 体内细胞来源异种移植模型中,PRAME mTCRCAR T细胞较未修饰T细胞对照实现强效白血病清除并改善生存。
核心结论
- 结果表明用新型PRAME mTCRCAR T细胞靶向PRAME具有可行性和疗效。
研究设计与样本
- 利用先前设计的TCR模拟抗体Pr20(识别PRAME ALY肽与HLA-A*02的复合物)的抗体序列构建PRAME mTCRCAR T细胞。
- 在表达PRAME的HLA-A2阳性AML细胞系(OCI-AML2、THP-1)和原代AML患者样本中测试PRAME mTCRCAR T细胞。
- 在体内细胞来源异种移植模型中评估PRAME mTCRCAR T细胞对白血病的清除和生存影响。
主要发现
- PRAME mTCRCAR T细胞在OCI-AML2和THP-1细胞系、表达PRAME抗原的HLA-A2细胞系以及原代AML患者样本中,与相应对照相比显示靶点特异性和HLA介导的体外活性。
- 体内细胞来源异种移植模型中,PRAME mTCRCAR T细胞治疗较未修饰T细胞对照显示强效白血病清除并改善生存。
- 干扰素γ处理靶细胞增加PRAME抗原表达,从而增强PRAME mTCRCAR T细胞的溶细胞活性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preferentially Expressed Antigen in Melanoma (PRAME), a cancer-testis antigen, provides an ideal target for immunotherapy in acute myeloid leukemia (AML). We have shown expression of PRAME in a significant subset of childhood and adult AML and lack of expression in normal hematopoiesis. Although an intracellular antigen, we developed a novel approach to target PRAME using a chimeric antigen receptor (CAR) construct encoding a targeting domain based on T-cell receptor (TCR) mimic antibodies that target the peptide-HLA complex. We used the antibody sequence from a previously designed TCR mimic (mTCR) antibody, Pr20, that recognizes the PRAME ALY peptide in complex with HLA-A∗02 and verified expression of PRAME in AML cell lines and primary AML blasts. Using the Pr20 antibody sequence, we developed CAR T cells (PRAME mTCRCAR T) to be tested against primary samples from patients with AML and AML cell lines that express the PRAME antigen in the context of HLA-A2 expression. In contrast to appropriate controls, PRAME mTCRCAR T cells demonstrate target-specific and HLA-mediated in vitro activity in OCI-AML2 and THP-1 cell lines, HLA-A2 cell lines expressing the PRAME antigen, and against primary AML patient samples. In vivo cell-derived xenograft models treated with PRAME mTCRCAR T cells demonstrated potent leukemia clearance and improved survival compared with unmodified T-cell controls. Furthermore, the cytolytic activity of PRAME mTCRCAR T cells was enhanced by treating the target cells with interferon gamma, which increases PRAME antigen expression. These results demonstrate the feasibility and efficacy of targeting PRAME with novel PRAME mTCRCAR T cells.
引用
- Kirkey DC, Loeb AM, Castro S, et al. Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia. Blood Adv. 2023. PMID: 35984639. doi:10.1182/bloodadvances.2022008304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。